Kaneki M, Kharbanda S, Pandey P, Yoshida K, Takekawa M, Liou J R, Stone R, Kufe D
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Mol Cell Biol. 1999 Jan;19(1):461-70. doi: 10.1128/MCB.19.1.461.
Human myeloid leukemia cells respond to 12-O-tetradecanoylphorbol-13-acetate (TPA) and other activators of protein kinase C (PKC) with induction of monocytic differentiation. The present studies demonstrated that treatment of U-937 and HL-60 myeloid leukemia cells with TPA, phorbol-12,13-dibutyrate, or bryostatin 1 was associated with the induction of stress-activated protein kinase (SAPK). In contrast, TPA-resistant TUR and HL-525 cell variants deficient in PKCbeta failed to respond to activators of PKC with the induction of SAPK. A direct role for PKCbeta in TPA-induced SAPK activity in TUR and HL-525 cells that stably express PKCbeta was confirmed. We showed that TPA induced the association of PKCbeta with MEK kinase 1 (MEKK-1), an upstream effector of the SAPK/ERK kinase 1 (SEK1)-->SAPK cascade. The results also demonstrated that PKCbeta phosphorylated and activated MEKK-1 in vitro. The functional role of MEKK-1 in TPA-induced SAPK activity was further supported by the demonstration that the expression of a dominant negative MEKK-1 mutant abrogated this response. These findings indicate that PKCbeta activation is necessary for activation of the MEKK-1-->SEK1-->SAPK cascade in the TPA response of myeloid leukemia cells.
人髓性白血病细胞对12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯(TPA)及蛋白激酶C(PKC)的其他激活剂产生反应,诱导单核细胞分化。目前的研究表明,用TPA、佛波醇 - 12,13 - 二丁酸酯或苔藓抑素1处理U - 937和HL - 60髓性白血病细胞与应激激活蛋白激酶(SAPK)的诱导有关。相比之下,对TPA耐药的TUR和缺乏PKCβ的HL - 525细胞变体在PKC激活剂作用下未能诱导产生SAPK。在稳定表达PKCβ的TUR和HL - 525细胞中,PKCβ在TPA诱导的SAPK活性中起直接作用得到了证实。我们发现TPA诱导PKCβ与MEK激酶1(MEKK - 1)结合,MEKK - 1是SAPK/ERK激酶1(SEK1)→SAPK级联反应的上游效应器。结果还表明,PKCβ在体外磷酸化并激活了MEKK - 1。显性负性MEKK - 1突变体的表达消除了这种反应,进一步支持了MEKK - 1在TPA诱导的SAPK活性中的功能作用。这些发现表明,在髓性白血病细胞的TPA反应中,PKCβ激活对于MEKK - 1→SEK1→SAPK级联反应的激活是必要的。